Evidence map›Paper›PMID 37069398›Full record

ArticleNature immunology2023

ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.

Yeonsun Hong, Brandon L Walling, Hye-Ran Kim, William S Serratelli, John R Lozada, Cooper J Sailer, Andrea M Amitrano, Kihong Lim, Raj Kumar Mongre, Kyun-Do Kim and 12 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
9.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 3 countries.

Yeonsun Hong *Department of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.
Brandon L Walling *Department of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.
Hye-Ran KimDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.
William S SerratelliDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.
John R LozadaDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.
Cooper J SailerDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.
Andrea M AmitranoDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-1101-872X
Kihong LimDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.ORCID http://orcid.org/0000-0001-6665-6422
Raj Kumar MongreDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.
Kyun-Do KimDepartment of Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon, Korea.
Tara CapeceDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.
Elena B LomakinaDepartment of Biomedical Engineering, University of Rochester Medical Center, Rochester, NY, USA.
Nicholas S ReillyDepartment of Physics and Astronomy, University of Rochester, Rochester, NY, USA.
Kevin VoDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA.
Scott A GerberDepartment of Surgery, University of Rochester, Rochester, NY, USA.
Tan-Chi FanInstitute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan, Taiwan.
Alice Lin-Tsing YuDepartment of Pediatrics/Hematology Oncology, University of California in San Diego, San Diego, CA, USA.
Patrick W OakesDepartment of Physics and Astronomy, University of Rochester, Rochester, NY, USA.
Richard E WaughDepartment of Biomedical Engineering, University of Rochester Medical Center, Rochester, NY, USA.ORCID http://orcid.org/0000-0003-2084-5740
Chang-Duk JunSchool of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.ORCID http://orcid.org/0000-0002-1372-9277
Patrick M ReaganWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Minsoo KimDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, USA. minsoo_kim@urmc.rochester.edu.ORCID http://orcid.org/0000-0002-9566-9385
University of Rochester · USUniversity of Rochester Medical Center · USChang Gung University · TWGwangju Institute of Science and Technology · KRKorea Research Institute of Chemical Technology · KRUniversity of California San Diego · US

Funding

Tissue regulation of T cell function - Reagents CoreP01AI102851 · NIAID · UNIVERSITY OF ROCHESTER · PI Iwijn De Vlaminck · 2014 to 2026
$26.0M
The T32 Predoctoral Training Program in Immunology (PTPI)T32AI007285 · NIAID · UNIVERSITY OF ROCHESTER · PI Scott Andrew Gerber, JACQUES Robert · 1986 to 2026
$7.6M
T cell migration and cardiovascular toxicity in immunotherapyR01AI147362 · NIAID · UNIVERSITY OF ROCHESTER · PI Minsoo Kim, Richard E Waugh · 2019 to 2026
$4.2M
NIAID NIH HHS P01 AI102851NIAID NIH HHS R01 AI147362NIAID NIH HHS T32 AI007285
6 · The paper itself

Abstract

Adoptive transfer of genetically engineered chimeric antigen receptor (CAR) T cells is becoming a promising treatment option for hematological malignancies. However, T cell immunotherapies have mostly failed in individuals with solid tumors. Here, with a CRISPR-Cas9 pooled library, we performed an in vivo targeted loss-of-function screen and identified ST3 β-galactoside α-2,3-sialyltransferase 1 (ST3GAL1) as a negative regulator of the cancer-specific migration of CAR T cells. Analysis of glycosylated proteins revealed that CD18 is a major effector of ST3GAL1 in activated CD8

Indexed as

Receptors, Chimeric AntigenAnimalsCD8-Positive T-LymphocytesCell Line, TumorCell MovementFemaleHumansImmunotherapy, AdoptiveLymphocyte Function-Associated Antigen-1MiceSpectrinLymphocyte Function-Associated Antigen-1Receptors, Chimeric AntigenSpectrin

Identifiers

PMID37069398
PMCPMC10515092
OpenAlexW4366085943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.